our capabilities
Uniquely integrated formulation, device and development capabilities
We effectively integrate all technologies and disciplines required to deliver an inhaled product.
Investors
Share price
Latest results
- 11 Sep 2018 | Investor centre Interim results for the six months ended 30 June 2018
- 09 Apr 2018 | Financial reports Annual report and accounts for the 12 months ended 31 December 2017
our strategic priorities
1
Maximising
pipeline value
- Leveraging rare product and device capabilities in lower risk, high-return programmes Focus on:
- Inhaled Generics
- Vectura enhanced therapies
2
Operational
excellence
- Simplifying processes and procedures to drive operational efficiency and reduce costs
- Managing R&D investment in line with guidance
3
Maximising
partnering value
- Seeking to partner existing programmes that no longer meet our investment criteria
- Partnering new generic and enhanced delivery development programmes
4
Strong financial
discipline
- Leveraging strong and growing cash flows from inhaled market portfolio
- Continued commitment to capital allocation discipline
5
High performance
culture
- Ensuring our culture and behaviour are supportive of our strategic objectives
case studies
We take products from a blank piece of paper right the way through to market, but the patient is always at the centre of what we do
Breelib™ highlights our integrated development capabilities which enable us to support the development of complex inhaled products throughout the development lifecycle, from initial partner interaction, right down to product launch support and digital solution development.
Given the inherent complexity associated with developing inhaled generics, we believe that there are only a handful of companies which have the necessary capabilities to successfully develop these programmes.
Vectura is one of a very limited number of companies globally outside of the big pharma organisations that has shown that it can succeed in bringing nebuliser device and formulation together